Recent advances in small‐molecule MuRF1 inhibitors have shown therapeutic potential across multiple conditions, attenuating muscle wasting in heart failure [20, 21, 22], cancer cachexia [23], corticosteroid‐induced myopathies [20] and diabetes [24]. The gene discussed is TRIM63; the disease is heart failure.